HMGCR and type 2 diabetes mellitus: While our results should be seen as tentative until trials have demonstrated benefit, associations of HMGCR variants show broad concordance with statin therapy for many continuous phenotypes (Würtz et al., 2016), and suggest that statins reduce the risk of coronary artery disease (Ference et al., 2016), increase risk of type 2 diabetes (Lotta et al., 2016), and increase risk of intracerebral hemorrhage (Sun et al., 2019; Allara et al., 2019a), as confirmed in clinical trials (ASCOT investigators et al., 2003; DIAGRAM Consortium et al., 2015; Collins et al., 2016).